Geoffrey R Oxnard MD
Associate Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7523goxnard@bu.edu
Sections
Hematology & Medical Oncology
Biography
Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.
Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.
Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.
Websites
Education
Medicine, MD, University of Chicago
Chemistry, AB, Harvard University
Publications
Battaglini J, AlDoughaim M, Li K, Patel J, Bhatt S, Everett P, Oxnard GR, Tapan U. Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer. Clin Transl Oncol. 2026 Jan 03. PMID: 41484568.
Published on 12/1/2025Shord SS, Chen C, Jin JY, Van Wart S, Martin SK, Davidson BA, Liu J, LoRusso PM, Oxnard GR. FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials. Clin Cancer Res. 2025 Dec 01; 31(23):4891-4898. PMID: 41036557.
Published on 11/29/2025Burns TF, Ammakkanavar NR, Hollebecque A, Lee DH, Koyama T, Cassier PA, Italiano A, Han JY, Singhal N, Takeuchi S, Heist RS, Deming D, Spira A, Chu Q, Sacher A, Fujiwara Y, Chisamore MJ, You AX, McNeely SC, Fink A, Chen A, Oxnard GR, Willard MD, Murciano-Goroff YR, Dragnev KH. Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC. J Thorac Oncol. 2026 Apr; 21(4):103528. PMID: 41319864.
Published on 6/13/2025Paweletz CP, Urvalek A, Ha M, Garg K, Bence Lin A, Szpurka AM, Sireci A, Oxnard GR, Janne PA. Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples. Clin Cancer Res. 2025 Jun 13; 31(12):2406-2412. PMID: 39887260.
Published on 6/3/2025Andrews HS, Zariffa N, Nishimura KK, Choi SH, Deng S, Eisele M, Espenschied CR, Goren EM, Guha M, Hong S, Juraeva D, Krämer N, Liu L, Martini JF, McKelvey BA, Oxnard GR, Pestano GA, Poole L, Rosenthal A, Szpurka AM, Vega DM, Ward C, Wijayawardana SR, Hoering A, Stewart MD, Allen JD. ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials. Clin Cancer Res. 2025 Jun 03; 31(11):2162-2172. PMID: 40261185.
Published on 4/10/2025Fujisawa T, Nakamura Y, Bando H, Morizane C, Ikeda M, Nonomura N, Matsubara N, Iwata H, Naito Y, Okano S, Aoki D, Harano K, Yamazaki N, Namikawa K, Ueno M, Kadowaki S, Oki E, Kato K, Komatsu Y, Satoh T, Esaki T, Denda T, Hamaguchi T, Yamazaki K, Matsuhashi N, Yasui H, Satake H, Nishina T, Takahashi N, Goto M, Sunakawa Y, Kato T, Otsuka T, Abutani H, Tukachinsky H, Lee JK, Oxnard GR, Kuramoto N, Horasawa S, Sakamoto Y, Taniguchi H, Yoshino T. Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study. JCO Precis Oncol. 2025 Apr; 9:e2400283. PMID: 40209142.
Published on 2/21/2025Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A. Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2025 May 20; 43(15):1758-1764. PMID: 39983053.
Published on 2/6/2025Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A, Subbiah V, Eskander RN, Carbone DP, Riess JW, Sammons S, Snider J, Bouzit L, Cho-Phan C, Price M, Li G, Quintanilha JCF, Huang RSP, Ross JS, Fabrizio D, Oxnard GR, Graf RP. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025 Feb 06; 13(2). PMID: 39915003.
Published on 8/5/2024Mack PC, Keller-Evans RB, Li G, Lofgren KT, Schrock AB, Trabucco SE, Allen JM, Tolba K, Oxnard GR, Huang RSP. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC. Oncologist. 2024 Aug 05; 29(8):e984-e996. PMID: 38401173.
Published on 6/3/2024Rolfo CD, Madison RW, Pasquina LW, Brown DW, Huang Y, Hughes JD, Graf RP, Oxnard GR, Husain H. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clin Cancer Res. 2024 Jun 03; 30(11):2452-2460. PMID: 38526394.
Media Mentions
Published on 12/2/2025
Published on 1/4/2024
Genomics Is a ‘Truly Powerful Tool’ for Changing Lung Cancer Outcomes
View full list of 2 media mentions.